

---

**CBE ID**

2468

**Title**

Adherence to Oral Diabetes Agents for Individuals with Diabetes Mellitus

**Project**

Primary Care and Chronic Illness

**Endorsement Status**

Endorsement Removed

**Is Under Review**

No

**Previous Endorsement Cycle**

Spring 2018

**Removal Date**

Sun, 03/25/2018 - 20:00

**Initial Endorsement**

Tue, 09/02/2014 - 13:37

**Steward**

Centers for Medicare & Medicaid Services

**1.0 New or Maintenance**

Maintenance

**1.1 Measure Structure**

Single Measure

**1.3 Electronic Clinical Quality Measure (eCQM)**

No

**1.6 Measure Description**

The measure addresses adherence to oral diabetes agents (ODA). The measure is reported as the percentage of eligible individuals with diabetes mellitus who had at least two prescriptions for a single oral diabetes agent or at least two prescriptions for multiple agents within a diabetes drug class and who have a Proportion of Days Covered (PDC) of at least 0.8 for at least one diabetes drug class during the measurement period (12 consecutive months)

**1.7 Measure Type**

Process

## 1.8 Level of Analysis

Clinician: Group/Practice, Health Plan, Integrated Delivery System, Population: Regional and State

## 1.9 Care Setting

Outpatient Services

## 1.14 Numerator

Individuals in the denominator with at least two prescriptions for oral diabetes agents, in any diabetes drug class, with a PDC of at least 0.8 for at least one diabetes drug class.

## 1.15 Denominator

Individuals at least 18 years of age as of the beginning of the measurement period with diabetes mellitus and at least two prescriptions for a single oral diabetes agent or at least two prescriptions for multiple agents within a diabetes drug class during the measurement period (12 consecutive months).

## 1.20 Types of Data Sources

Claims Data, Electronic Health Data, Other

## 6.1.2 Current or Planned Use(s)

Not in use, Public Reporting, Quality Improvement (Internal to the specific organization), Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

## 6.1.3 Current Use(s)

Not in use, Public Reporting, Quality Improvement (Internal to the specific organization), Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

## Exclusions

We excluded the following individuals from the denominator:

Individuals with polycystic ovaries, gestational diabetes, or steroid-induced diabetes who do not have a face-to-face visit with a diagnosis of diabetes in any setting during the measurement period.

### Exclusion 1

Individuals with a diagnosis of polycystic ovaries who do not have a visit with a diagnosis of diabetes in any setting during the measurement period\*; and,

### Exclusion 2

Individuals with a diagnosis of gestational diabetes or steroid-induced diabetes who do not have a visit with a diagnosis of diabetes mellitus in any setting during the measurement period.

\*Adapted from NCQA HEDIS 2013 (2013). Note: HEDIS uses a look-back period of one year prior to the measurement period for both the prescription data and diagnosis.

## Measure Disclaimer

This performance measure does not establish a standard of medical care and has not been tested for all potential applications.

**Planned Use**

Public Reporting, Quality Improvement (Internal to the specific organization), Quality Improvement with Benchmarking (external benchmarking to multiple organizations)

**Risk Adjustment**

No risk adjustment or risk stratification

**Target Population**

Dual eligible beneficiaries, Elderly, Populations at Risk

**Steward Organization**

Centers for Medicare & Medicaid Services

**Steward POC email**

Helen.Dollar-Maples@cms.hhs.gov